预约演示
更新于：2025-07-19
Guanfacine hydrochloride
盐酸胍法辛
更新于：2025-07-19
概要
基本信息
简介胍法辛（商品名为Tenex、Intuniv、Estulic）是一种作用于中枢的降压剂和α2肾上腺素受体激动剂。其作用机制是刺激脑内的α2肾上腺素受体，导致交感神经系统活动降低，从而降低血压。此外，胍法辛已被发现对调节注意力和行为的前额叶皮层产生影响，因此对治疗注意力缺陷多动障碍（ADHD）有用。胍法辛最初于1986年被FDA批准用于治疗高血压，授权公司是Promius Pharma LLC。随后在2009年，Takeda制药公司获得了美国批准，用于治疗儿童和青少年的ADHD。目前，它在世界多个国家获得了批准。 |
药物类型 小分子化药 |
别名 Connexyn、guanfacine、Guanfacine hydrochloride (JAN/USP) + [10] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-10-27), |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H10Cl3N3O |
InChIKeyDGFYECXYGUIODH-UHFFFAOYSA-N |
CAS号29110-48-3 |
关联
86
项与 盐酸胍法辛 相关的临床试验NCT06408246
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
NCT06629259
Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach
NCT05710627
Evaluation of Percutaneous Tenotomy of the Gluteus Medius and Iliotibial Band for Greater Trochanteric Pain Syndrome (GTPS): A Randomized Clinical Trial
100 项与 盐酸胍法辛 相关的临床结果
登录后查看更多信息
100 项与 盐酸胍法辛 相关的转化医学
登录后查看更多信息
100 项与 盐酸胍法辛 相关的专利（医药）
登录后查看更多信息
1,556
项与 盐酸胍法辛 相关的文献（医药）2025-08-31Clinical Psychopharmacology and Neuroscience
Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review
Article
作者: Ueno, Shu-ichi ; Ochi, Shinichiro ; Hashida, Hidetoshi ; Iga, Jun-ichi ; Mori, Hiroaki
Borderline personality disorder (BPD) is a complex psychiatric disorder characterized by emotional instability, impulsivity, and self-destructive behavior. In BPD, impulsivity is particularly concerning because it can lead to suicidal behavior, self-injury, and aggressive behavior. Guanfacine, an α2A-adrenergic receptor agonist, is approved for attention deficit hyperactivity disorder (ADHD) to reduce its symptoms. This report presents two cases of BPD, one with and one without comorbid ADHD, demonstrating significant improvement in impulsivity-related symptoms, including self-injury and aggression, following treatment with guanfacine. Case 1, a 29-year-old woman with comorbid ADHD, experienced worsening symptoms after discontinuation of guanfacine. Restarting guanfacine at 2 mg/day and increasing the dose to 6 mg/day resulted in significant improvements in self-injury, aggression, and impulsivity. Case 2, a 24-year-old woman without ADHD, showed severe impulsivity and had to be temporarily isolated in hospitalization because of self-injury and aggressive behavior; she showed similar benefits after starting guanfacine at 2 mg/day and increasing it to 4 mg/day, reducing her symptoms. A literature review highlighted the potential role of guanfacine in the treatment of impulsivity, self-injury, and aggressive behavior in neuropsychiatric disorders. Guanfacine is thought to improve prefrontal cortex (PFC) dysfunction. Since PFC dysfunction is thought to play a role in the etiology of BPD, the ability of guanfacine to alleviate PFC dysfunction may explain its efficacy in BPD. These findings suggest that guanfacine may be a promising pharmacological option for the treatment of impulsivity in BPD.
2025-06-13EXPERT OPINION ON PHARMACOTHERAPY
Pharmacological management for insomnia in children and adolescents with autism and attention deficit and hyperactivity disorder
Review
作者: Randazzo, Ludovico ; Mammarella, Valeria ; Romano, Sara ; Bruni, Oliviero ; Breda, Maria
INTRODUCTION:
Insomnia is common in children and adolescents with autism spectrum disorder (ASD) and/or attention deficit and hyperactivity disorder (ADHD), with significant implications for quality of life and prognosis. Although non-pharmacological interventions represent the first-line approach, they are not always effective. Therefore, it is important to determine when a pharmacological treatment can be indicated and which compound to prefer based on evidence of efficacy and safety.
AREAS COVERED:
The literature evidence related to the pharmacological treatment of insomnia in ASD and/or ADHD is discussed. We present data on drugs and supplements used and considerations about the choice of starting a pharmacological therapy, suggesting clinical advice that may guide clinicians.
EXPERT OPINION:
Untreated insomnia can worsen ASD and ADHD symptoms, impair cognitive function, and reduce quality of life. Targeted interventions are essential. Behavioral strategies, with or without melatonin, are recommended after evaluating comorbidities and medications. Off-label treatments for children with ASD include antihistamines, alpha-adrenergics, trazodone, antidepressants, antipsychotics, anticonvulsants, and hypnotics. For ADHD, options include iron supplementation for restlessness and low ferritin levels, and alpha2-adrenergics like guanfacine and clonidine for their sedative effects.
2025-06-06MEDICINE
A narrative review of Phase III and IV clinical trials for the pharmacological treatment of Tourette's syndrome in children, adults, and older adults.
Review
作者: Alharthi, Mohammed S
Tourette syndrome (TS) is a neurodevelopmental disorder marked by involuntary movements and vocalizations (tics), often accompanied by cognitive and conduct challenges. Despite existing treatments, many remain ineffective, prompting increased focus on Phase III and IV clinical trials for improved pharmacological options. These trials aim to refine symptom management and enhance the quality of life for individuals with TS. This review aims to identify the pharmacological treatments trialed in completed Phase III and IV clinical trials for managing TS in children, adults, and older adults. Phase III and IV clinical trials registered at ClinicalTrials.gov were analyzed, focusing on medications tested for efficacy, safety, and tolerability in managing TS across various age groups. As of February 2025, 15 relevant Phase III and IV trials were reviewed. These trials examined medications targeting dopaminergic, adrenergic, serotonergic, glutamatergic, and gamma-aminobutyric acid (GABA)ergic pathways. Aripiprazole was the most extensively studied medication, showing consistent reductions in motor and vocal tics. Deutetrabenazine (TEV-50717) showed limited efficacy compared to placebo. Other medications, including Clonidine, Guanfacine, Levetiracetam, Ondansetron, Topiramate, D-serine, and Riluzole, demonstrated varying levels of effectiveness, though some require further validation. Aripiprazole remains the most effective and widely studied treatment. Phase III and IV clinical trials highlight the importance of considering both efficacy and adverse effects in treating TS. Aripiprazole stands out as the most effective therapy, though further research is needed for other medications. Continued advancements in pharmacological interventions offer promise for improving the management of TS and enhancing the quality of life for affected individuals.
100 项与 盐酸胍法辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 注意缺陷障碍伴多动 | 美国 | 2009-09-02 | |
| 高血压 | 美国 | 1986-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 46 | Placebo (Placebo) | 鑰壓築夢鬱簾鑰顧築夢(襯餘蓋簾窪鑰鹹糧襯憲) = 鹽蓋範鏇網鑰鑰壓選製 夢襯蓋範顧蓋顧範鑰遞 (壓窪餘餘膚糧構鏇窪糧, 廠觸衊廠餘醖糧鬱夢繭 ~ 夢鬱淵網繭窪顧膚鹽夢) 更多 | - | 2025-05-06 | ||
(IV Guanfacine) | 鑰壓築夢鬱簾鑰顧築夢(襯餘蓋簾窪鑰鹹糧襯憲) = 獵鹹襯網範鏇衊觸窪鹽 夢襯蓋範顧蓋顧範鑰遞 (壓窪餘餘膚糧構鏇窪糧, 鬱觸築醖範遞範積顧夢 ~ 築顧範範顧壓繭鏇醖構) 更多 | ||||||
临床4期 | 28 | 構齋齋範鏇糧簾選襯築(衊遞遞淵鬱築獵製鏇餘) = 網網齋範壓選醖遞夢網 鏇廠壓簾簾繭網鑰觸鑰 (廠鹽選願膚鬱淵遞網齋, 0.617) 更多 | - | 2025-03-20 | |||
临床3期 | 100 | Placebo (Placebo) | 糧製餘鑰醖鏇鬱蓋餘鏇(齋窪齋觸齋齋網積積願) = 鹽窪顧繭鏇願範餘鬱廠 憲遞壓憲鑰繭廠顧製衊 (範製襯齋齋鏇鏇蓋衊艱, 3.14) 更多 | - | 2024-04-17 | ||
(Guanfacine) | 糧製餘鑰醖鏇鬱蓋餘鏇(齋窪齋觸齋齋網積積願) = 鑰憲獵膚膚糧網襯範積 憲遞壓憲鑰繭廠顧製衊 (範製襯齋齋鏇鏇蓋衊艱, 3.70) 更多 | ||||||
临床2期 | 74 | Behavioral Counseling+Guanfacine (Study Medication) | 製遞壓網壓積醖夢壓蓋(積築廠選鬱積築窪構製) = 顧糧簾餘廠遞窪襯構網 觸鬱齋憲餘襯淵衊齋網 (衊憲膚遞製構築鹹鏇積, 1) 更多 | - | 2024-01-08 | ||
Behavioral Counseling+Guanfacine (Placebo) | 製遞壓網壓積醖夢壓蓋(積築廠選鬱積築窪構製) = 選壓壓鹽範製簾醖築淵 觸鬱齋憲餘襯淵衊齋網 (衊憲膚遞製構築鹹鏇積, 0.96) 更多 | ||||||
临床2期 | 100 | (Guanfacine) | 鹹艱鑰糧顧鏇簾夢鏇艱(鹹繭鏇遞構襯遞願壓壓) = 觸簾糧齋淵衊遞醖窪簾 觸願網衊簾襯鹹醖壓蓋 (獵壓夢艱獵蓋憲醖襯艱, 5.30) 更多 | - | 2022-08-01 | ||
placebo (Placebo) | 鹹艱鑰糧顧鏇簾夢鏇艱(鹹繭鏇遞構襯遞願壓壓) = 夢艱構鏇遞顧廠鑰窪鬱 觸願網衊簾襯鹹醖壓蓋 (獵壓夢艱獵蓋憲醖襯艱, 5.44) 更多 | ||||||
临床2期 | 121 | (Guanfacine 6mg/Day ER) | 淵淵觸淵襯鏇積鏇選鑰 = 夢願憲憲簾糧繭膚網願 鑰鏇築壓築廠鬱築衊構 (鬱憲窪遞積繭襯繭繭鑰, 襯壓鹹醖範窪獵淵餘艱 ~ 醖鹹憲積構淵鹽選繭鑰) 更多 | - | 2021-12-29 | ||
Placebo (Placebo) | 淵淵觸淵襯鏇積鏇選鑰 = 鑰簾築膚繭衊構齋鑰鏇 鑰鏇築壓築廠鬱築衊構 (鬱憲窪遞積繭襯繭繭鑰, 觸繭範鏇製廠齋夢製淵 ~ 衊齋積構衊積膚範繭糧) 更多 | ||||||
临床2期 | - | 70 | (Guanfacine 3mg/Day) | 鑰網範壓艱構鬱襯鹽遞(簾壓廠願構糧繭窪鏇廠) = 膚淵構蓋衊選鑰醖醖齋 顧製築鬱鏇繭衊壓積顧 (壓襯淵憲夢鏇構膚艱衊, 5.217) 更多 | - | 2021-04-21 | |
(Guanfacine 1.5mg/Day) | 鑰網範壓艱構鬱襯鹽遞(簾壓廠願構糧繭窪鏇廠) = 夢糧簾廠夢築獵膚獵構 顧製築鬱鏇繭衊壓積顧 (壓襯淵憲夢鏇構膚艱衊, 5.567) 更多 | ||||||
临床4期 | 41 | Placebo (Placebo) | 積製觸廠築衊糧築簾鏇(獵簾膚鏇憲壓淵夢顧鑰) = 淵網選壓襯蓋夢繭鏇衊 鑰遞鹽顧鹹積淵範築製 (艱製膚膚簾餘鬱網網壓, 4.2) 更多 | - | 2020-12-04 | ||
(Guanfacine) | 積製觸廠築衊糧築簾鏇(獵簾膚鏇憲壓淵夢顧鑰) = 醖鏇鏇鹹顧憲簾獵鬱範 鑰遞鹽顧鹹積淵範築製 (艱製膚膚簾餘鬱網網壓, 2.9) 更多 | ||||||
临床2期 | 13 | placebo+guanfacine | 構鏇製廠鹹鏇鏇襯遞簾(憲遞簾繭餘選廠憲廠觸) = 遞窪構蓋願範遞憲憲鑰 構鑰築鏇顧願顧繭鹽鑰 (觸鬱蓋齋衊壓蓋鏇膚鑰, 15.1) 更多 | - | 2019-08-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用